MedTrace Logo

The Efficacy and Safety of Udenafil in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy

NCT03142542 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2017-05-05

No results posted yet for this study

Summary

This study evaluates the efficacy and safety of Udenafil dosed once a day in patients with erectile dysfunction after bilateral nerve-sparing radical prostatectomy.

Conditions

  • Prostate Cancer With Radical Prostatectomy

Interventions

DRUG

ZYDENA TAB.75mg(Udenafil 75mg)

ZYDENA TAB.75mg(Udenafil 75mg): by mouth, Once daily, for 32 weeks

DRUG

Placebo Oral Tablet

Placebo Oral Tablet: by mouth, Once daily, for 32 weeks

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    collaborator INDUSTRY

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • SeongSoo Jeon, PhD · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-31
Primary Completion
2019-05-31
Completion
2019-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03142542 on ClinicalTrials.gov